お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:医薬品受託製造・開発の世界市場 (~2025年):サービス区分 (医薬品・生物製剤・APIなど)・エンドユーザー (大手製薬・中小規模製薬・ジェネリック製薬・CRO)・地域別
市場調査レポート
商品コード
995931

医薬品受託製造・開発の世界市場 (~2025年):サービス区分 (医薬品・生物製剤・APIなど)・エンドユーザー (大手製薬・中小規模製薬・ジェネリック製薬・CRO)・地域別

Pharmaceutical Contract Development and Manufacturing Market (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma,CRO)-Global Forecast to 2025

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 192 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.63円
医薬品受託製造・開発の世界市場 (~2025年):サービス区分 (医薬品・生物製剤・APIなど)・エンドユーザー (大手製薬・中小規模製薬・ジェネリック製薬・CRO)・地域別
出版日: 2021年03月10日
発行: MarketsandMarkets
ページ情報: 英文 192 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の医薬品受託製造・開発の市場規模は予測期間中7.7%のCAGRで推移し、2020年の1007億米ドルから、2025年には1461億米ドルの規模に成長すると予測されています。

ジェネリック医薬品に対する需要の高まり、医薬品のR&Dへの投資の増加、CDMOによる高度な製造技術への投資、生物製剤への需要の高まり、特殊医薬品への注目の高まり、核医学分野の成長、細胞・遺伝子治療の進歩などの要因が同市場の成長を推進する見通しです。

サービス区分別では、生物製剤製造サービスの部門が最大のCAGRを示す見通しです。ワクチンおよびバイオシミラーへの需要の高まりが同部門の成長を牽引しています。また、地域別では、アジア太平洋地域が予測期間中最大のCAGRを示すと予測されています。製造業の成長、政府による有利な政策、大手企業の戦略的拡大、特許切れの医薬品の重要性の高まり、高度なスキルを有する人材の存在などの要因が同地域の成長を牽引しています。

当レポートでは、世界の医薬品受託製造・開発の市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、市場規模の推移・予測、サービス・エンドユーザー・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 市場機会
    • 課題
    • 動向
  • バリューチェーン分析
  • エコシステム
  • サプライチェーン
  • COVID-19の影響
  • 規制評価
  • ポーターのファイブフォース分析

第6章 市場分析・予測:サービス別

  • 医薬品製造サービス
    • API製造サービス
    • FDF製造サービス
  • 医薬品開発サービス
  • 生物製剤製造サービス
    • 生物API製造サービス
    • 生物FDF製造サービス

第7章 市場分析・予測:エンドユーザー別

  • 大規模製薬企業
  • 中小規模製薬企業
  • ジェネリック製薬企業
  • その他

第8章 市場分析・予測:地域・主要国別

  • 欧州
    • ドイツ
    • イタリア
    • フランス
    • 英国
    • スイス
    • スペイン
    • その他
  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • インド
    • 韓国
    • 日本
    • その他
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

  • 概要
  • 主要企業の収益分配
  • 市場シェア分析
  • 競合リーダーシップマッピング
  • スタートアップ/SME評価マトリックス
  • 企業のサービスフットプリント
  • 企業の地理的フットプリント
  • 競合シナリオ

第10章 企業プロファイル

  • 主要企業
    • LONZA GROUP
    • THERMO FISHER SCIENTIFIC INC.
    • CATALENT
    • RECIPHARM AB
    • ABBVIE
    • SIEGFRIED HOLDING AG
    • EVONIK INDUSTRIES
    • BOEHRINGER INGELHEIM
    • PIRAMAL PHARMA SOLUTIONS
    • SAMSUNG BIOLOGICS
    • WUXI APPTEC (WUXI STA)
    • FUJIFILM HEALTHCARE
  • その他の企業
    • VETTER PHARMA INTERNATIONAL
    • FAMAR HEALTH CARE SERVICES
    • AENOVA GROUP
    • ALMAC GROUP
    • CAMBREX
    • CORDENPHARMA
    • BIOVECTRA
    • ALBANY MOLECULAR RESEARCH

第11章 付録

目次
Product Code: PH 7263

The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, growing focus on specialty medicines, growth in the nuclear medicines sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.

"The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market, byend user, during the forecast period"

The pharmaceutical contract development and manufacturing market is segmented intobig pharmaceutical companies, small & medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users.The small and medium-sized pharmaceutical companies segment accounted for the highest growth rate in the pharmaceutical contract development and manufacturing market in 2020. This segment's high growth can be attributed to the increasing number of emerging pharmaceutical companies that lack the in-house capabilities to manufacture and develop complex formulations and drug products.

"Biologics manufacturing services segment accounted for the highest CAGR"

Based on service, the pharmaceutical contract development and manufacturing market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing servicessegment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.

"Asia Pacific: The fastest-growing countryin thepharmaceutical contract development and manufacturing market"

Thepharmaceutical contract development and manufacturing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. This growth can be attributed to factors such as growth in the manufacturing sector, favorable government regulations, growing strategic expansions from leading companies, increasing emphasis on off-patent drugs, and the presence of a highly skilled workforce.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80%and Demand Side 20%
  • By Designation: C-level - 25%, D-level - 20%, and Others - 55%
  • By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report:

  • Thermo Fisher Scientific Inc. (US)
  • Catalent, Inc. (US)
  • Lonza Group Ltd. (Switzerland)
  • Recipharm AB (Sweden)
  • Siegfried Holding AG (Switzerland)
  • WuXiAppTec (China)
  • Samsung Biologics (South Korea)
  • Boehringer Ingelheim International GmbH (Germany)
  • Piramal Pharma Solutions (India)
  • Vetter Pharma International GmbH (Germany)
  • FAMAR Health Care Services (France)
  • AbbVie Inc. (US)
  • Aenova Group (Germany)
  • Almac Group (UK)
  • Evonik Industries AG (Germany)
  • Cambrex Corporation (US)
  • CordenPharma International (Germany)
  • Albany Molecular Research Inc. (AMRI) (US)
  • FUJIFILM Corporation (Japan)
  • BioVectra (Canada)

Research Coverage:

This report provides a detailed picture of thepharmaceutical contract development and manufacturing market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmaceutical contract development and manufacturing marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 1 BREAKDOWN OF PRIMARIES: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • 2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
    • FIGURE 2 DATA TRIANGULATION METHODOLOGY
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 MARKET SIZE ESTIMATION APPROACH
    • FIGURE 3 COMPANY REVENUE ANALYSIS-BASED ESTIMATION
    • FIGURE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE (USD BILLION): FINAL MARKET SIZE
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 5 FINAL CAGR PROJECTIONS (2020-2025)
  • 2.4 INSIGHTS FROM PRIMARIES
    • FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY SERVICE, 2019
    • FIGURE 8 BIOLOGICS MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2019
    • FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2020 VS. 2025 (USD BILLION)
    • FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET

4 PREMIUM INSIGHTS

  • 4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW
    • FIGURE 11 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
  • 4.2 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES TO COMMAND THE LARGEST SHARE OF THE EUROPEAN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER
    • FIGURE 13 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
  • 4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES BETWEEN 2020 & 2025

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Patent expiry and increasing demand for generic drugs
      • 5.2.1.2 Increasing investments in pharmaceutical R&D
    • FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010-2020)
    • FIGURE 17 GLOBAL R&D SPENDING (2016-2020)
      • 5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Increasing demand for biological therapies
      • 5.2.2.2 Growth in the nuclear medicine sector
      • 5.2.2.3 Growing demand for cell and gene therapies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Introduction of serialization
    • 5.2.4 TRENDS
      • 5.2.4.1 Expansion in emerging countries
      • 5.2.4.2 CDMO industry consolidation
    • TABLE 1 LIST OF ACQUISITIONS
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 18 VALUE CHAIN ANALYSIS OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 5.4 ECOSYSTEM MARKET MAP
    • FIGURE 19 ECOSYSTEM OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 5.5 SUPPLY CHAIN
  • 5.6 IMPACT OF THE COVID-19 PANDEMIC ON THE GROWTH OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
    • 5.6.1 IMPACT ON THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • FIGURE 20 PRE-COVID VS. POST-COVID-19 SCENARIO, 2019-2021
  • 5.7 REGULATORY ASSESSMENT
    • 5.7.1 INTRODUCTION
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 DEGREE OF COMPETITION

6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE

  • 6.1 INTRODUCTION
    • TABLE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
  • 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
    • TABLE 4 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 5 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
      • 6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
    • TABLE 6 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
    • TABLE 7 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 8 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.1 Parenteral/injectable manufacturing services
        • 6.2.2.1.1 Need for high levels of expertise and growing drug development activities are driving the demand for contract manufacturing
    • TABLE 9 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.2 Tablet manufacturing services
        • 6.2.2.2.1 Shifting manufacturing requirements and the need to streamline production processes are driving market growth
    • TABLE 10 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.3 Capsule manufacturing services
        • 6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
    • TABLE 11 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.4 Oral liquid manufacturing services
        • 6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to opt for outsourcing
    • TABLE 12 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.5 Semi-solid manufacturing services
        • 6.2.2.5.1 Demand for specific manufacturing facilities to boost the outsourcing of semi-solids
    • TABLE 13 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
      • 6.2.2.6 Other formulations manufacturing services
    • TABLE 14 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.3 DRUG DEVELOPMENT SERVICES
    • 6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
    • TABLE 15 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • 6.4 BIOLOGICS MANUFACTURING SERVICES
    • TABLE 16 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 17 BIOLOGICS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.4.1 BIOLOGICS API MANUFACTURING SERVICES
      • 6.4.1.1 Market for biologics API manufacturing is still in the nascent phase
    • TABLE 18 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
      • 6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing
    • TABLE 19 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER

  • 7.1 INTRODUCTION
    • TABLE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 7.2 BIG PHARMACEUTICAL COMPANIES
    • 7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
    • TABLE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
    • 7.3.1 GROWING DEVELOPMENT OF BIOLOGIC DRUGS AND HIGH PRICING PRESSURE TO BOOST MARKET GROWTH
    • TABLE 22 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.4 GENERIC PHARMACEUTICAL COMPANIES
    • 7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
    • TABLE 23 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • 7.5 OTHER END USERS
    • TABLE 24 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2018-2025 (USD MILLION)

8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION

  • 8.1 INTRODUCTION
    • FIGURE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
    • TABLE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2018-2025 (USD MILLION)
  • 8.2 EUROPE
    • FIGURE 22 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 26 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 27 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 28 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 29 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 30 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 31 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.1 GERMANY
      • 8.2.1.1 High healthcare expenditure and increased pharmaceutical production to support market growth
    • TABLE 32 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 33 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 34 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 35 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 36 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.2 ITALY
      • 8.2.2.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
    • TABLE 37 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 38 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 39 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 40 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 41 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.3 FRANCE
      • 8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
    • TABLE 42 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 43 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 44 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 45 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 46 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.4 UK
      • 8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
    • TABLE 47 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 48 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 49 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 50 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 51 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.5 SWITZERLAND
      • 8.2.5.1 Large volume of pharmaceutical production and growing scope for generics to provide growth opportunities
    • TABLE 52 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 53 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 54 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 55 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 56 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.6 SPAIN
      • 8.2.6.1 Increase in biologics production to support market growth
    • TABLE 57 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 58 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 59 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 60 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 61 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.2.7 REST OF EUROPE
    • TABLE 62 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 63 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 64 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 65 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 66 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.3 NORTH AMERICA
    • TABLE 67 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 68 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 69 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 70 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 71 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 72 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.3.1 US
      • 8.3.1.1 The US dominates the North American pharmaceutical contract development and manufacturing market
    • TABLE 73 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 74 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 75 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 76 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 77 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.3.2 CANADA
      • 8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper the market growth
    • TABLE 78 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 79 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 80 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 81 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 82 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.4 ASIA PACIFIC
    • FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
    • TABLE 83 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 85 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 86 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 87 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.1 CHINA
      • 8.4.1.1 Favorable government regulations are fueling market growth in China
    • TABLE 89 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 90 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 91 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 92 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 93 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.2 INDIA
      • 8.4.2.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
    • TABLE 94 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 95 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 96 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 97 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 98 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.3 SOUTH KOREA
      • 8.4.3.1 Government investments are a key contributor to market growth in South Korea
    • TABLE 99 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 100 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 101 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • 8.4.4 JAPAN
      • 8.4.4.1 Growing generics demand and government initiatives to drive the demand for contract manufacturing of drugs
    • TABLE 102 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 103 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 104 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 105 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 106 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
    • 8.4.5 REST OF ASIA PACIFIC
    • TABLE 107 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 108 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 109 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 110 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 111 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.5 LATIN AMERICA
    • 8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
    • TABLE 112 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 113 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 114 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 115 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 116 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2018-2025 (USD MILLION)
  • 8.6 MIDDLE EAST & AFRICA
    • 8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR CONTRACT MANUFACTURERS IN THE REGION
    • TABLE 117 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2018-2025 (USD MILLION)
    • TABLE 118 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
    • TABLE 119 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)

9 COMPETITIVE LANDSCAPE

  • 9.1 OVERVIEW
  • 9.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 9.3 MARKET SHARE ANALYSIS
    • FIGURE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANK, BY KEY PLAYER, 2019
    • TABLE 120 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
  • 9.4 COMPETITIVE LEADERSHIP MAPPING
    • 9.4.1 STARS
    • 9.4.2 EMERGING LEADERS
    • 9.4.3 PERVASIVE PLAYERS
    • 9.4.4 PARTICIPANTS
    • FIGURE 26 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT (2019)
  • 9.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2019
    • 9.5.1 PROGRESSIVE COMPANIES
    • 9.5.2 STARTING BLOCKS
    • 9.5.3 RESPONSIVE COMPANIES
    • 9.5.4 DYNAMIC COMPANIES
    • FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: STARTUP/SME EVALUATION MATRIX, 2019
  • 9.6 COMPANY SERVICE FOOTPRINT
    • TABLE 121 SERVICE PORTFOLIO ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
  • 9.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
    • TABLE 122 GEOGRAPHIC REVENUE MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2019)
  • 9.8 COMPETITIVE SCENARIO
    • TABLE 123 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, MAY 2019-OCTOBER 2020
    • TABLE 124 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, MARCH 2019-JANUARY 2021
    • TABLE 125 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHERS, MAY 2019-NOVEMBER 2020

10 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**
  • 10.1 MAJOR PLAYERS
    • 10.1.1 LONZA GROUP
    • TABLE 126 LONZA GROUP: BUSINESS OVERVIEW
    • FIGURE 28 LONZA GROUP: COMPANY SNAPSHOT (2020)
    • TABLE 127 LONZA GROUP: SERVICES OFFERED
    • 10.1.2 THERMO FISHER SCIENTIFIC INC.
    • TABLE 128 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019)
    • TABLE 129 THERMO FISHER SCIENTIFIC: SERVICES OFFERED
    • 10.1.3 CATALENT
    • TABLE 130 CATALENT: BUSINESS OVERVIEW
    • FIGURE 30 CATALENT: COMPANY SNAPSHOT (2020)
    • TABLE 131 CATALENT: SERVICES OFFERED
    • 10.1.4 RECIPHARM AB
    • TABLE 132 RECIPHARM AB: BUSINESS OVERVIEW
    • FIGURE 31 RECIPHARM AB: COMPANY SNAPSHOT (2019)
    • TABLE 133 RECIPHARM AB: SERVICES OFFERED
    • 10.1.5 ABBVIE
    • TABLE 134 ABBVIE: BUSINESS OVERVIEW
    • FIGURE 32 ABBVIE: COMPANY SNAPSHOT (2019)
    • TABLE 135 ABBVIE: SERVICES OFFERED
    • 10.1.6 SIEGFRIED HOLDING AG
    • TABLE 136 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
    • FIGURE 33 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2019)
    • TABLE 137 SIEGFRIED HOLDING AG: SERVICES OFFERED
    • 10.1.7 EVONIK INDUSTRIES
    • TABLE 138 EVONIK INDUSTRIES: BUSINESS OVERVIEW
    • FIGURE 34 EVONIK INDUSTRIES: COMPANY SNAPSHOT (2019)
    • TABLE 139 EVONIK INDUSTRIES: SERVICES OFFERED
    • 10.1.8 BOEHRINGER INGELHEIM
    • TABLE 140 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
    • FIGURE 35 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2019)
    • TABLE 141 BOEHRINGER INGELHEIM: SERVICES OFFERED
    • 10.1.9 PIRAMAL PHARMA SOLUTIONS
    • TABLE 142 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
    • FIGURE 36 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2019)
    • TABLE 143 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED
    • 10.1.10 SAMSUNG BIOLOGICS
    • TABLE 144 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2019)
    • TABLE 145 SAMSUNG BIOLOGICS: SERVICES OFFERED
    • 10.1.11 WUXI APPTEC (WUXI STA)
    • TABLE 146 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 38 WUXI APPTEC: COMPANY SNAPSHOT (2019)
    • TABLE 147 WUXI APPTEC: SERVICES OFFERED
    • 10.1.12 FUJIFILM HEALTHCARE
    • TABLE 148 FUJIFILM HEALTHCARE: BUSINESS OVERVIEW
    • FIGURE 39 FUJIFILM HEALTHCARE: COMPANY SNAPSHOT (2019)
    • TABLE 149 FUJIFILM HEALTHCARE: SERVICES OFFERED
  • 10.2 OTHER PLAYERS
    • 10.2.1 VETTER PHARMA INTERNATIONAL
    • TABLE 150 VETTER PHARMA INTERNATIONAL: BUSINESS OVERVIEW
    • TABLE 151 VETTER PHARMA INTERNATIONAL: SERVICES OFFERED
    • 10.2.2 FAMAR HEALTH CARE SERVICES
    • TABLE 152 FAMAR HEALTH CARE SERVICES: BUSINESS OVERVIEW
    • TABLE 153 FAMAR HEALTH CARE SERVICES: SERVICES OFFERED
    • 10.2.3 AENOVA GROUP
    • TABLE 154 AENOVA GROUP: BUSINESS OVERVIEW
    • TABLE 155 AENOVA GROUP: SERVICES OFFERED
    • 10.2.4 ALMAC GROUP
    • 10.2.5 CAMBREX
    • 10.2.6 CORDENPHARMA
    • 10.2.7 BIOVECTRA
    • 10.2.8 ALBANY MOLECULAR RESEARCH
  • *Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX

  • 11.1 DISCUSSION GUIDE
  • 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.3 AVAILABLE CUSTOMIZATIONS
  • 11.4 RELATED REPORTS
  • 11.5 AUTHOR DETAILS 196
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.